Capital Management Corp VA reduced its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 4.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 225,844 shares of the biopharmaceutical company's stock after selling 10,625 shares during the period. Bristol Myers Squibb comprises 2.4% of Capital Management Corp VA's investment portfolio, making the stock its 15th largest holding. Capital Management Corp VA's holdings in Bristol Myers Squibb were worth $13,774,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Lipe & Dalton boosted its holdings in shares of Bristol Myers Squibb by 0.4% in the 1st quarter. Lipe & Dalton now owns 56,999 shares of the biopharmaceutical company's stock valued at $3,476,000 after buying an additional 230 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of Bristol Myers Squibb by 43.1% in the 1st quarter. Jennison Associates LLC now owns 5,240,877 shares of the biopharmaceutical company's stock valued at $319,641,000 after buying an additional 1,578,043 shares in the last quarter. Pzena Investment Management LLC boosted its holdings in shares of Bristol Myers Squibb by 1.2% in the 1st quarter. Pzena Investment Management LLC now owns 13,458,826 shares of the biopharmaceutical company's stock valued at $820,854,000 after buying an additional 157,527 shares in the last quarter. Forum Financial Management LP boosted its holdings in shares of Bristol Myers Squibb by 10.9% in the 1st quarter. Forum Financial Management LP now owns 18,729 shares of the biopharmaceutical company's stock valued at $1,142,000 after buying an additional 1,845 shares in the last quarter. Finally, Kingsview Wealth Management LLC grew its position in Bristol Myers Squibb by 187.2% during the 1st quarter. Kingsview Wealth Management LLC now owns 91,080 shares of the biopharmaceutical company's stock worth $5,555,000 after purchasing an additional 59,362 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
BMY has been the subject of several analyst reports. Jefferies Financial Group cut their price target on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 target price (down from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Finally, Piper Sandler began coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target on the stock. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $57.69.
View Our Latest Report on BMY
Insider Buying and Selling at Bristol Myers Squibb
In related news, EVP Samit Hirawat bought 4,250 shares of the business's stock in a transaction that occurred on Friday, April 25th. The shares were bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president directly owned 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.09% of the stock is owned by corporate insiders.
Bristol Myers Squibb Trading Down 1.4%
Shares of BMY stock traded down $0.66 on Friday, hitting $47.40. The company had a trading volume of 10,713,205 shares, compared to its average volume of 12,764,805. The firm has a market cap of $96.46 billion, a P/E ratio of 17.75, a P/E/G ratio of 2.44 and a beta of 0.36. The stock's 50-day moving average is $47.47 and its two-hundred day moving average is $52.91. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. Bristol Myers Squibb Company has a twelve month low of $41.90 and a twelve month high of $63.33.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The company had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter in the prior year, the firm posted ($4.40) earnings per share. The business's quarterly revenue was down 5.6% on a year-over-year basis. On average, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.
Bristol Myers Squibb Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be issued a $0.62 dividend. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.23%. Bristol Myers Squibb's payout ratio is currently 92.88%.
Bristol Myers Squibb Profile
(
Free Report)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
Before you consider Bristol Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.
While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
